CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,911 enrolled
Drug / intervention
Transfluthrin +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04795648
NCT04795648N/ACompleted
CompareCT.gov

Spatial Repellent Products for Control of Vector Borne Diseases

University of Notre Dame·interventional·Posted Mar 12, 2021·Updated Apr 2, 2024

In Brief

A clinical study evaluating Transfluthrin and Placebo for Malaria. Completed, enrolled 1,911 participants across 2 sites.

Detailed Summary

The primary objective of the study is to demonstrate and quantify the protective efficacy of a single Spatial Repellent (SR) product, in reducing malaria infection in a human cohort. The study design will be a prospective cluster Randomized Control Trial (cRCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesMali
CollaboratorsS.C. Johnson & Son, Inc., fhiClinical, Malaria Research and Training Center, Bamako, Mali, Catholic Relief Services

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 12, 2021
Enrollment StartJul 8, 2021
Primary CompletionMar 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.3 years ago

Interventions

Transfluthrindevice

Passive emanator with formulated transfluthrin

Placebodevice

Passive emanator with formulated inert ingredients